P/E at 30.41 vs Industry's 36.91: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount to Industry P/E

The stock’s P/E ratio of 30.41 represents a discount of approximately 17.6% relative to the sector average of 36.91. This valuation gap suggests that the market is pricing in either subdued growth expectations or heightened risk compared to peers within the Pharmaceuticals & Biotechnology sector. Such a premium or discount often reflects investor sentiment on earnings sustainability and sector cyclicality. In this case, the discount may indicate caution despite the company’s established market presence and mid-cap status with a market capitalisation of ₹97,991 crores.

This valuation context raises the question: previously rated Hold, what is Dr Reddys Laboratories Ltd’s current rating? The four-parameter analysis factors in the valuation premium and recent performance trends.

Performance Across Timeframes: Divergent Momentum

Examining returns across multiple periods reveals a nuanced picture. Over the past year, Dr Reddys Laboratories Ltd has declined by 2.31%, almost in line with the Sensex’s 2.29% fall. However, the short-term performance is more concerning. The stock has fallen 14.56% over the last month and 10.76% over three months, while the Sensex has gained 0.53% and 0.95% respectively in those periods. This divergence suggests recent headwinds that have disproportionately affected the stock.

Interestingly, the one-week performance shows a modest recovery of 2.20%, outperforming the Sensex’s 0.99% gain. This 5% surge partially reverses a 14.56% monthly decline — is this a genuine recovery or a relief rally that will fade at the 50 DMA? — the moving average configuration provides the clearest answer.

Moving Average Configuration: Mixed Technical Signals

The technical setup for Dr Reddys Laboratories Ltd is characterised by its position relative to key moving averages. The stock currently trades above its 5-day moving average but remains below the 20-day, 50-day, 100-day, and 200-day moving averages. This configuration typically indicates a short-term bounce within a broader downtrend, reflecting tentative buying interest but persistent medium- to long-term selling pressure.

Such a pattern often signals that while immediate momentum may be improving, the stock has yet to break out of its longer-term resistance levels. This technical divergence aligns with the recent performance data, where short-term gains contrast with sustained medium-term weakness. Is this a recovery or a dead-cat bounce?

Sector Performance Context

The Pharmaceuticals & Biotechnology sector has seen mixed results in recent earnings seasons. Out of 13 stocks that have declared results, seven reported positive outcomes, five were flat, and one was negative. This distribution suggests a broadly stable sector environment with pockets of strength and weakness. How does Dr Reddys Laboratories Ltd’s performance compare within this sector backdrop? Its underperformance in recent months contrasts with the sector’s overall resilience, highlighting company-specific challenges or market perceptions.

Rating Reassessment and Historical Performance

Dr Reddys Laboratories Ltd was previously rated Hold by MarketsMOJO before its rating was updated on 13 Jul 2026. The current Mojo Score stands at 36.0, with a Mojo Grade of Sell. This shift reflects the combination of valuation, performance, and technical factors outlined above.

Looking at longer-term returns, the stock has underperformed the Sensex significantly. Over three years, it has gained 3.53% compared to the Sensex’s 19.75%. The five-year return is 22.20%, well below the Sensex’s 45.00%, and over ten years, the stock’s 94.79% gain trails the Sensex’s 180.29%. This persistent underperformance may contribute to the cautious market valuation and the recent rating reassessment. Should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Intraday and Recent Price Movements

On 6 Aug 2026, the stock declined by 0.38%, underperforming the Sensex which gained 0.15%. Over the past week, however, the stock outperformed the index with a 2.20% gain versus 0.99% for the Sensex. This volatility underscores the stock’s current uncertain momentum and the importance of monitoring technical indicators closely.

Conclusion: What the Data Collectively Shows

The data for Dr Reddys Laboratories Ltd paints a picture of a stock trading at a valuation discount to its sector, yet grappling with recent underperformance and a mixed technical outlook. The short-term bounce above the 5-day moving average contrasts with sustained weakness below longer-term moving averages, signalling a tentative recovery within a broader downtrend. The rating reassessment from Hold to Sell reflects these complexities, alongside the stock’s lagging returns relative to the Sensex over multiple time horizons.

Given these factors, what is the current rating for Dr Reddys Laboratories Ltd? This question remains central for investors weighing the stock’s valuation against its recent performance and technical signals.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →